eicosapentaenoic acid ethyl ester has been researched along with Diabetes Mellitus, Type 2 in 21 studies
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dietary cod-liver oil containing eicosapentaenoic acid is effective on microvascular albumin leakage in diabetic patients with albuminuria." | 9.08 | Long-term effect of eicosapentaenoic acid ethyl (EPA-E) on albuminuria of non-insulin dependent diabetic patients. ( Mori, M; Ohtani, K; Sato, N; Shimizu, H; Shimomura, Y; Tanaka, Y, 1995) |
| "This study examined the effects of eicosapentaenoic acid (EPA) administration on the prevention of early hearing loss in diabetic mice." | 8.31 | Prevention of progressive hearing loss in a mouse model of diabetes by oral intake of eicosapentaenoic acid ethyl ester. ( Hashimoto, M; Matsuura, T; Sugahara, K; Tsuda, J; Yamamoto, Y; Yamashita, H, 2023) |
| "The purpose of the present study was to test whether hyperlipidaemia and insulin resistance in type 2 diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats can be improved by dietary supplementation with purified eicosapentaenoic acid (EPA) or oleic acid (OA)." | 7.71 | Effect of eicosapentaenoic acid ethyl ester v. oleic acid-rich safflower oil on insulin resistance in type 2 diabetic model rats with hypertriacylglycerolaemia. ( Ishimura, N; Mawatari, K; Minami, A; Nakaya, Y; Okada, K; Sakamoto, S; Takishita, E, 2002) |
| "We investigated the effect of long-term administration of highly purified eicosapentaenoic acid ethyl ester (EPA-E), an n-3 polyunsaturated fatty acid derived from fish oil, in comparison to lard on the development of hypertension and insulin resistance in Dahl salt-sensitive (Dahl-S) rats fed a high-sucrose diet (HSD), a model of salt-sensitive hypertension." | 7.70 | Effect of highly purified eicosapentaenoic acid ethyl ester on insulin resistance and hypertension in Dahl salt-sensitive rats. ( Ikeda, Y; Ishikawa, T; Mori, Y; Murakawa, Y; Nobukata, H; Shibutani, Y; Tajima, N; Yokoyama, J, 1999) |
| "We investigated the effect of long-term administration of highly purified eicosapentaenoic acid ethyl ester (EPA-E), an n-3 polyunsaturated fatty acid derived from fish oil, in comparison to the effects of lard, olive oil, safflower oil, or distilled water as the control on the development of insulin resistance in Otsuka Long-Evans Tokushima Fatty (OLETF) rats, a model of spontaneous non-insulin-dependent diabetes mellitus (NIDDM) with obesity." | 7.69 | Influence of highly purified eicosapentaenoic acid ethyl ester on insulin resistance in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous non-insulin-dependent diabetes mellitus. ( Hata, S; Ikeda, Y; Ishikawa, T; Katoh, S; Mori, Y; Murakawa, Y; Nobukata, H; Shibutani, Y; Tajima, N; Yokoyama, J, 1997) |
| "Dietary cod-liver oil containing eicosapentaenoic acid is effective on microvascular albumin leakage in diabetic patients with albuminuria." | 5.08 | Long-term effect of eicosapentaenoic acid ethyl (EPA-E) on albuminuria of non-insulin dependent diabetic patients. ( Mori, M; Ohtani, K; Sato, N; Shimizu, H; Shimomura, Y; Tanaka, Y, 1995) |
| "This study examined the effects of eicosapentaenoic acid (EPA) administration on the prevention of early hearing loss in diabetic mice." | 4.31 | Prevention of progressive hearing loss in a mouse model of diabetes by oral intake of eicosapentaenoic acid ethyl ester. ( Hashimoto, M; Matsuura, T; Sugahara, K; Tsuda, J; Yamamoto, Y; Yamashita, H, 2023) |
| "The purpose of the present study was to test whether hyperlipidaemia and insulin resistance in type 2 diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats can be improved by dietary supplementation with purified eicosapentaenoic acid (EPA) or oleic acid (OA)." | 3.71 | Effect of eicosapentaenoic acid ethyl ester v. oleic acid-rich safflower oil on insulin resistance in type 2 diabetic model rats with hypertriacylglycerolaemia. ( Ishimura, N; Mawatari, K; Minami, A; Nakaya, Y; Okada, K; Sakamoto, S; Takishita, E, 2002) |
| "We investigated the effect of long-term administration of highly purified eicosapentaenoic acid ethyl ester (EPA-E), an n-3 polyunsaturated fatty acid derived from fish oil, in comparison to lard on the development of hypertension and insulin resistance in Dahl salt-sensitive (Dahl-S) rats fed a high-sucrose diet (HSD), a model of salt-sensitive hypertension." | 3.70 | Effect of highly purified eicosapentaenoic acid ethyl ester on insulin resistance and hypertension in Dahl salt-sensitive rats. ( Ikeda, Y; Ishikawa, T; Mori, Y; Murakawa, Y; Nobukata, H; Shibutani, Y; Tajima, N; Yokoyama, J, 1999) |
| "We investigated the effect of long-term administration of highly purified eicosapentaenoic acid ethyl ester (EPA-E), an n-3 polyunsaturated fatty acid derived from fish oil, in comparison to the effects of lard, olive oil, safflower oil, or distilled water as the control on the development of insulin resistance in Otsuka Long-Evans Tokushima Fatty (OLETF) rats, a model of spontaneous non-insulin-dependent diabetes mellitus (NIDDM) with obesity." | 3.69 | Influence of highly purified eicosapentaenoic acid ethyl ester on insulin resistance in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous non-insulin-dependent diabetes mellitus. ( Hata, S; Ikeda, Y; Ishikawa, T; Katoh, S; Mori, Y; Murakawa, Y; Nobukata, H; Shibutani, Y; Tajima, N; Yokoyama, J, 1997) |
| "The elderly patients with type 2 diabetes suffer more adverse drug events than young adults due to pharmacokinetic and pharmacodynamic changes associated with aging." | 1.48 | Benefits of combination low-dose pioglitazone plus fish oil on aged type 2 diabetes mice. ( Chiba, K; Hirako, S; Iizuka, Y; Kim, H; Matsumoto, A; Wada, M, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (38.10) | 18.2507 |
| 2000's | 1 (4.76) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 4 (19.05) | 2.80 |
| Authors | Studies |
|---|---|
| Pedro-Botet, J | 3 |
| Barrios, V | 3 |
| Sánchez-Margalet, V | 3 |
| Tamargo, J | 3 |
| Arrieta, F | 3 |
| Gámez, JM | 3 |
| Gimeno-Orna, JA | 3 |
| Escobar, C | 3 |
| Gómez-Doblas, JJ | 3 |
| Pérez, A | 3 |
| Kim, JM | 1 |
| Bhatt, DL | 2 |
| Dagogo-Jack, S | 1 |
| Cherney, DZI | 1 |
| Cosentino, F | 1 |
| McGuire, DK | 1 |
| Pratley, RE | 1 |
| Liu, CC | 1 |
| Cater, NB | 1 |
| Frederich, R | 1 |
| Mancuso, JP | 1 |
| Cannon, CP | 1 |
| Matsuura, T | 1 |
| Sugahara, K | 1 |
| Yamamoto, Y | 1 |
| Tsuda, J | 1 |
| Hashimoto, M | 1 |
| Yamashita, H | 1 |
| Boden, WE | 1 |
| Toth, PP | 1 |
| Ray, KK | 1 |
| Chapman, MJ | 1 |
| Lüscher, TF | 1 |
| Brinton, EA | 2 |
| Ballantyne, CM | 2 |
| Guyton, JR | 1 |
| Philip, S | 1 |
| Doyle, RT | 1 |
| Juliano, RA | 1 |
| Mosca, L | 1 |
| Takenouchi, Y | 1 |
| Ohtake, K | 1 |
| Nobe, K | 1 |
| Kasono, K | 1 |
| Iizuka, Y | 1 |
| Kim, H | 1 |
| Hirako, S | 1 |
| Chiba, K | 1 |
| Wada, M | 1 |
| Matsumoto, A | 1 |
| Lan, NSR | 1 |
| Fegan, PG | 1 |
| Yeap, BB | 1 |
| Rankin, JM | 1 |
| Watts, GF | 1 |
| Al Rifai, M | 1 |
| Jia, X | 1 |
| Al-Mallah, MH | 1 |
| Miedema, MD | 1 |
| Martin, SS | 1 |
| Virani, SS | 1 |
| Bays, HE | 1 |
| Kastelein, JJ | 1 |
| Braeckman, RA | 1 |
| Soni, PN | 1 |
| Caffrey, MK | 1 |
| Bot, M | 1 |
| Pouwer, F | 1 |
| Assies, J | 1 |
| Jansen, EH | 1 |
| Beekman, AT | 1 |
| de Jonge, P | 1 |
| Shimizu, H | 3 |
| Ohtani, K | 3 |
| Tanaka, Y | 3 |
| Sato, N | 3 |
| Mori, M | 3 |
| Shimomura, Y | 1 |
| Kashima, K | 1 |
| Westerveld, HT | 1 |
| de Graaf, JC | 1 |
| van Breugel, HH | 1 |
| Akkerman, JW | 1 |
| Sixma, JJ | 1 |
| Erkelens, DW | 1 |
| Banga, JD | 1 |
| Fukatsu, A | 1 |
| Uehara, Y | 1 |
| Miwa, H | 1 |
| Yamamoto, M | 1 |
| Futata, T | 1 |
| Kan, K | 1 |
| Asano, T | 1 |
| Mori, Y | 2 |
| Murakawa, Y | 2 |
| Katoh, S | 1 |
| Hata, S | 1 |
| Yokoyama, J | 2 |
| Tajima, N | 2 |
| Ikeda, Y | 2 |
| Nobukata, H | 2 |
| Ishikawa, T | 2 |
| Shibutani, Y | 2 |
| Minami, A | 1 |
| Ishimura, N | 1 |
| Sakamoto, S | 1 |
| Takishita, E | 1 |
| Mawatari, K | 1 |
| Okada, K | 1 |
| Nakaya, Y | 1 |
| Okuda, Y | 1 |
| Mizutami, M | 1 |
| Tanaka, K | 1 |
| Isaka, M | 1 |
| Yamashita, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Effect of Two Doses of AMR101 (Ethyl Icosapentate) on Fasting Serum Triglyceride Levels in Patients With Persistent High Triglyceride Levels (≥ 200 mg/dL and < 500 mg/dL) Despite Statin Therapy[NCT01047501] | Phase 3 | 702 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Median percent change from baseline to Week 12 in serum Apolipoprotein B levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 1.6 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -2.2 |
| Placebo | 7.1 |
Median percent change from baseline to Week 12 in serum Lipoprotein-associated Phospholipase A2 levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | -1.8 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -12.8 |
| Placebo | 6.7 |
Median percent change from baseline to Week 12 in serum low density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 2.4 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | 1.5 |
| Placebo | 8.8 |
Median percent change from baseline to Week 12 in serum non-high density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 2.4 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -5.0 |
| Placebo | 9.8 |
Median percent change from baseline to Week 12 in fasting serum triglyceride levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | -5.6 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -17.5 |
| Placebo | 5.9 |
Median percent change from baseline to Week 12 in serum very low-density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 1.6 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -12.1 |
| Placebo | 15.0 |
2 reviews available for eicosapentaenoic acid ethyl ester and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; Humans; Hydroxymethylglut | 2020 |
Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Benzhydryl Compounds; Cardi | 2019 |
6 trials available for eicosapentaenoic acid ethyl ester and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; Female; Humans; Hyd | 2018 |
Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.
Topics: Biomarkers; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Eicosap | 2013 |
Supplementation with eicosapentaenoic omega-3 fatty acid does not influence serum brain-derived neurotrophic factor in diabetes mellitus patients with major depression: a randomized controlled pilot study.
Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Diabetes Melli | 2011 |
Long-term effect of eicosapentaenoic acid ethyl (EPA-E) on albuminuria of non-insulin dependent diabetic patients.
Topics: Acetylglucosaminidase; Administration, Oral; Aged; Albuminuria; Analysis of Variance; beta 2-Microgl | 1995 |
Effects of low-dose EPA-E on glycemic control, lipid profile, lipoprotein(a), platelet aggregation, viscosity, and platelet and vessel wall interaction in NIDDM.
Topics: Adenosine Diphosphate; Analysis of Variance; Blood Glucose; Blood Platelets; Blood Viscosity; Collag | 1993 |
Increased plasma thrombin-antithrombin III complex levels in non-insulin dependent diabetic patients with albuminuria are reduced by ethyl icosapentatenoate.
Topics: Albuminuria; Antithrombin III; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; Humans; Peptide Hyd | 1995 |
13 other studies available for eicosapentaenoic acid ethyl ester and Diabetes Mellitus, Type 2